![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Avectas
Main focus: Next-generation delivery technology for gene editing
Company stage: Pre-clinical
Diseases: Cancer
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Dublin, Ireland
Website: https://avectas.com/
Partners: ONK Therapeutics
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_avectas_805dede051_fbf12ccf45.png)
Avectas develops its proprietary SOLUPORE® technology to genetically engineer T cells and natural killer (NK) cells to enable the next generation of gene-modified cell therapies. The company has established a collaboration with ONK Therapeutics, however, it yet has to disclose any proprietary or partnered therapeutic programmes.